Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Radiation and Evorpacept (ALX148) in Combination With Pembrolizumab In Patients With Previously Untreated Locally Advanced, Resectable, HPVOPC (Human Papilloma Virus Oropharynx Cancer)

NCT05787639 is registered in ClinicalTrials.gov with University of California, San Diego as lead sponsor.

NCT NCT05787639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05787639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Radiation and Evorpacept (ALX148) in Combination With Pembrolizumab In Patients With Previously Untreated Locally Advanced, Resectable, HPVOPC (Human Papilloma Virus Oropharynx Cancer)
Lead sponsor
University of California, San Diego
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 23, 2024
Completion date
October 31, 2029
Enrollment
28 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

oropharynx cancer